Avapritinib demonstrated high anti-tumor activity (objective response rate [ORR] 79%) in patients with PDGFRA D842V-mutant GIST, suggesting that it may be effective in first-, or subsequent, lines of treatment in Chinese patients with advanced/metastatic PDGFRA D842V-mutant GIST, which represents a previously untreatable GIST subtype. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.